Investor Tej Kohli Expands ‘Venture Philanthropy’ Into 3d-printed Bionic Arms
29.11.2019 10:00:00 EET | Business Wire | Press release
Investor Tej Kohli is to fund the purchase of ten bionic arms for children with limb differences in the UK. The Tej Kohli Foundation hopes that its commitment to fund arms for ten children over the next 5 months as part of its ‘Future Bionics’ program will highlight how assistive technology can substantially improve the lives and confidence of young people living with disabilities. The Tej Kohli Foundation hopes to inspire and influence other healthcare institutions to follow this lead and discover the advanced 3D-printed technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005558/en/
Tej Kohli Foundation co-Founder Wendy Kohli, Tilly Lockey wearing Open Bionics arms, Tej Kohli Foundation co-Founder Tej Kohli, future Hero Arm recipient Jacob Pickering, future Hero Arm recipient Harris Gribble (Photo: Business Wire)
In England the National Health Service (‘NHS’) currently provides a single-grip myoelectric-controlled (‘myo’) prosthesis at a cost of approximately £8,000. However, the Open Bionics Hero Arm can be controlled with the electrical signals generated by a user’s muscles and has superior multi-grip functionality that enables users to perform many more everyday activities.
The Open Bionics Hero Arm costs £10,000 through a private prosthetics clinic in the UK, whereas other advanced multi-grip bionic hands cost £30,000 - £60,000. The Tej Kohli Foundation will spend an initial £100,000 to launch its ‘Future Bionics’ programme, which will enable ten British children to access not just a superior technology, but a better life.
The first Hero Arm recipient is 10-year-old Jacob Pickering from Blackburn, who will receive his new Hero Arm just in time for Christmas. Jacob was born without his right arm as a result of amniotic band syndrome. All Jacob has spoken about for the past month is the Hero Arm, and his father David is “completely overwhelmed” that Jacob has been selected for a donation and claims that it will “change Jacob’s life”. The second Hero Arm recipient is 14-year-old Harris Gribble from Exeter, who is a keen Rugby and Cricket player.
The lightweight Hero Arm is currently the only multi-grip myo prosthetic arm that is available for paediatric use. The enhanced ability of the user to be able to personalise their 3D-printed Open Bionics Hero Arm is also a huge boost to mental well-being and to perceived social acceptance. This is particularly important for younger people.
Investor Tej Kohli first discovered Bristol-based Open Bionics when he invested into ‘Rewired’, a robotics-focused venture studio ‘with a humanitarian bent’ that was a very-early backer of Open Bionics in 2017.
Tej Kohli, Co-Founder of the Tej Kohli Foundation said:
“We started the Tej Kohli Foundation in 2005 with a project to provide daily meals for 1,000 children in Costa Rica. Since then the Tej Kohli Foundation has supported projects all over the world and helped tens of thousands of people, especially those living with disability. This gift of ten bionic arms is the first project that we have ever initiated in the UK. I see it as just the beginning, and my hope is that this gift will help to highlight the positive difference that technology can make to the confidence and prospects of a younger person. We’re doing this as an example, but we hope that others will follow our lead. These technologies are now so accessible and affordable that healthcare organisations such as the NHS should do more to embrace and improve access to them for disabled young people.”
Samantha Payne, Co-Founder and COO of Open Bionics said:
“We’re really grateful to the Tej Kohli Foundation for pledging to fund advanced bionic arms for ten children in the UK. These children are amongst dozens of people with upper limb differences in the UK fundraising right now for a Hero Arm. We've worked really hard to achieve a price point for the device that is acceptable for existing NHS budgets for prosthetic provision, and we very much hope the NHS sees how helpful these devices are and will begin offering them to the people who need them.”
Children and adults with below-elbow limb differences can register their interest at www.openbionics.com.
Images and profiles of the recipients of the Hero Arms can be downloaded here: https://www.dropbox.com/sh/wakjc66nz1ljjpb/AADwtFqgu7j-xhEtTRzYuBdsa?dl=0
About Open Bionics
Open Bionics was founded in 2014 by Joel Gibbard and Samantha Payne with the goal of developing affordable, assistive devices that enhance the human body. In other words, Open Bionics turns disabilities into superpowers. The Bristol-based bionics company is known globally for using 3D printing and 3D scanning, along with some clever software and design, to make advanced, affordable and accessible bionic limbs. In May 2018, the company released the Hero Arm, the world’s first medically approved 3D-printed bionic arm, and the very first multi-grip bionic arm for children as young as eight years old. The Hero Arm is available now through private prosthetic clinics all around the world. Open Bionics have a development contract with NHS England, with the aim of offering the Hero Arm on the NHS in the UK. They also have royalty-free licensing agreements with Disney, Marvel, Lucasfilm, Eidos Montreal and Twentieth Century Fox, making science fiction a reality.
About the Tej Kohli Foundation
Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness, which disproportionately impacts young people in poorer countries. Since 2015 the Foundation has funded free corneal transplants in poor communities in India; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness.
Through its ‘Impact Initiatives’ the Tej Kohli Foundation also makes direct interventions into the lives of young people whose confidence and prospects can be substantially improved. Previous ‘Impact Initiatives’ have included financial support for disabled children in Costa Rice, feeding schoolchildren at after-school clubs in poor communities, and also producing a short film to highlight the plight of young people in India living with a rare genetic disease.
http://www.tejkohlifoundation.com
About Tej Kohli
Tej Kohli is a London-based investor and philanthropist who first rose to success selling technology solutions and payments software during the dot com boom. His current focus is as a real estate investor within the world’s newly emerging technology hubs, and as a backer of high-impact AI, robotics and genomics ventures that have the potential to transform lives and change the world. He is also a major esports investor.
Tej Kohli is a distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.
END
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191128005558/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
kohliventures@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
